Demographic and tumor characteristics of statin users and nonusers in PCaP
| Statin nonusers (n = 1,205) | Statin users (n = 725) | P | |
|---|---|---|---|
| Age at diagnosis, mean (SD) | 62 (8) | 65 (7) | <0.0001 |
| Race | |||
| CA | 604 (50) | 408 (56) | 0.009 |
| AA | 601 (50) | 317 (44) | |
| Site | |||
| North Carolina | 602 (50) | 325 (45) | 0.029 |
| Louisiana | 603 (50) | 400 (55) | |
| Clinical stage | |||
| T1 | 679 (56) | 389 (54) | 0.249 |
| T2–T4 | 526 (44) | 336 (46) | |
| PSA, median (IQR) | 5.8 (4.3–9.8) | 5.3 (4.1–7.6) | <0.0001 |
| Biopsy Gleason sum | |||
| ≤3 + 4 | 941 (79) | 590 (82) | 0.101 |
| ≥4 + 3 | 256 (21) | 132 (18) | |
| Aggressive prostate cancer | |||
| Low/intermediate | 972 (81) | 614 (85) | 0.025 |
| High | 233 (19) | 111 (15) | |
| Prostate cancer screening frequency | |||
| Never | 278 (23) | 82 (11) | <0.0001 |
| ≤1 Test per year | 365 (30) | 260 (36) | |
| >1 Test per year | 562 (47) | 383 (53) | |
| Family history of prostate cancer (first-degree relative)a | |||
| No | 811 (73) | 503 (75) | 0.214 |
| Yes | 304 (27) | 164 (25) | |
| Education | |||
| Less than high school | 234 (19) | 125 (17) | 0.320 |
| High school graduate | 299 (25) | 171 (24) | |
| College graduate or some college | 672 (56) | 428 (59) | |
| Incomeb | |||
| <$20,000 | 238 (22) | 126 (19) | 0.331 |
| $20,000–$50,000 | 361 (33) | 234 (35) | |
| $50,000–$80,000 | 221 (20) | 145 (22) | |
| >$80,000 | 284 (25) | 158 (24) | |
| Smoking status | |||
| Never | 407 (34) | 243 (34) | <0.0001 |
| Former | 585 (49) | 407 (56) | |
| Current | 213 (18) | 75 (10) | |
| BMI (kg/m2) | |||
| <30 | 793 (66) | 400 (55) | <0.0001 |
| ≥30 | 412 (34) | 325 (45) | |
| Charlson comorbidity index | |||
| 0 | 697 (58) | 281 (39) | <0.0001 |
| ≥1 | 508 (42) | 444 (61) | |
| Cardiovascular disease | |||
| No | 1,104 (92) | 508 (71) | <0.0001 |
| Yes | 95 (8) | 210 (29) | |
| Diabetes | |||
| No | 1,022 (85) | 494 (69) | <0.0001 |
| Yes | 179 (15) | 226 (31) | |
| Dietary cholesterol intake (mg/day) | 288 (198–406) | 269 (179–368) | 0.0001 |
| Percent saturated fat intake, mean (SD) | 10.6 (2.7) | 10.7 (2.7) | 0.811 |
| Nonstatin cholesterol-lowering drug use | |||
| None | 1,123 (93) | 563 (78) | <0.0001 |
| Niacin/fibrate/ezetimibe | 82 (7) | 162 (22) |